This review summarizes the multidisciplinary management of adult soft tissue sarcomas, highlighting surgery as the mainstay for localized disease and systemic therapies for advanced disease.
Answers are grounded in this paper and cite their sources.
Reinforces current multidisciplinary standards for adult soft tissue sarcomas; leaves open need for prospective trials on novel systemic therapies.
Sarcomas are uncommon malignancies accounting for about 1% of all adult malignancies. Sarcomas are a heterogeneous group of tumors which includes more than 100 different subtypes. Surgery is the mainstay therapy for localized disease. In selected patients the combination of surgery with radiotherapy achieves better local control and offers the best chance of cure. Systemic treatment including cytotoxic chemotherapy or targeted therapies remains the mainstay therapy for most patients with advanced disease. There are a wide variety of clinical situations, such that an individualized treatment plan must be defined by a multidisciplinary tumor board. Treatment decisions should take into consideration the histology, site of disease, stage, performance status, treatment goals, and the patient's wishes. The management of patients should be carried out in a center with expertise in the treatment of sarcomas for optimal outcome. This review will cover the different treatment modalities of adult soft tissue sarcomas.
No takes yet. Share an insight, caveat, or question.
Arifi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: